ERBB2 and ductal breast carcinoma in situ: In addition, both KCSmart and GISTIC2 identified gains/amplifications of FGFR1, MYC, CCND1, ERBB2, and PTK6, as well as losses as CDKN2A/B, BRCA1, and MAP3K1 to occur more frequently in DCIS-MIND models with invasive progression (Figures 4B and S4C).